Advancing Public Health and Medical Innovation Through Global Collaboration.
The Advanced Therapies Research Institute (SinaGen) was established on August 20, 2024, with the mission of enhancing public health and advancing medical science. Registered as a non-commercial organization with registration number 57990 and national ID 14013671601, the institute operates under the supervision of the Tehran Companies and Non-Commercial Institutions Registration Office.
Targeted and Innovative Treatments
SinaGen delivers precise, personalized treatments using advanced genetics, cell therapy, and targeted drugs.


Dr. Sina Salari
(Chairman & Co-Founder)
SinaGen leads in advanced therapies with innovation and precision.
SinaGen brings 9 years of expertise in advancing therapies through collaborations across healthcare, research, and global networks.
SinaGen is a leader in advanced therapies and medical research.
SinaGen is dedicated to advancing healthcare with innovative therapies, fostering collaboration, and delivering impactful solutions for a healthier future.
23rd - 25th October, 2024
Presence of SinaGen at the 2nd International Congress of Cancer Genomics (CGC2024) in Tehran, 2024.8th December 2024
Signing of a Collaboration Agreement between SinaGen Institute and the Cardio-Oncology Research Center.20th August, 2024
Establishment of SinaGen26th November 2024
Collaboration Agreement between SinaGen Institute and Motamed Cancer Research Institute.14th – 15th May 2025
The 9th International Congress on Personalized Medicine and the 1st International Congress on Advanced Therapies in Iran.
We have many reviews from our satisfied clients.

Kathleen Smith

Van Hunter

Macquarie Telecom
